Virological determinants of drug resistance in real-world patients with chronic HCV infection

现实世界慢性 HCV 感染患者耐药性的病毒学决定因素

• 批准号: nhmrc : 1066537
• 负责人: A/Pr Fabio Luciani
• 金额: $ 36.72万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/virological-determinants-drug-hcv-infection/455242
• 关键词: Virological; determinants; drug; resistance; real

New treatments for hepatitis C virus (HCV) infection are emerging. These drugs directly target key events in the viral life cycle. While these drugs are effective, the ability of HCV to mutate means that drug resistance can arise, leading to treatment failure. This is most likely in patients who do not respond to interferon-based therapy. This proposal will use new, highly sensitive sequencing approaches to identify the viral mutations and evolutionary pathways that lead to drug resistance.

丙型肝炎病毒（HCV）感染的新疗法正在出现。这些药物直接针对病毒生命周期中的关键事件。虽然这些药物是有效的，但HCV的突变能力意味着可能出现耐药性，导致治疗失败。这最有可能发生在对基于干扰素的治疗无反应的患者中。该提案将使用新的、高度敏感的测序方法来识别导致耐药性的病毒突变和进化途径。